Resolving diagnostic and prognostic uncertainty to help prevent, detect, and treat gastrointestinal diseases.
Our novel diagnostic tests combine proprietary and well-validated epigenetic biomarkers with advanced data analytics to provide clinicians with actionable data to better guide patient care. Our tests are accurate, inexpensive, and convenient.
Solving critical clinical problems with the power of diagnostics.
Our technology provides patients and their physicians secure, accurate, and actionable diagnostic data.
Democratizing precision medicine.
We’re focused on developing solutions addressing specific clinical needs using well-validated, affordable methods that can be made available to all.
A paradigm shift towards earlier detection.
Our technology detects early molecular warning indicators, so we can detect precancerous conditions before they become malignant.
Our initial products will aid in the detection and prevention of esophageal cancer. By providing improved diagnostic and prognostic insight, we plan to help save many of the 509,000 individuals that fall ill to these cancers each year.
A prognostic genomics-based tissue assay to assess future neoplastic progression in patients with Barrett’s esophagus.
A non-invasive and inexpensive test to diagnose precancerous Barrett’s esophagus, and esophageal cancers.
Board of Directors
Capsulomics is led by experts in molecular biomarker assays and built upon 30+ years of research progress.
Dan Lunz, MBA
Co-Founder & CEO
Stephen Meltzer, MD
Co-Founder & CMO
John E. Niederhuber, MD
Caroline Popper, MD, MPH
Otis W Brawley, MD
James Stover, PhD
Sean R Tunis, MD
Richard Friedberg, MD
Qubely – A Full-fledged Gutenberg Builder
Have questions? Get in touch with us today.